Invalidity dossier
US 9885698
Near-infrared lasers for non-invasive monitoring of glucose, ketones, HbA1C, and other blood constituents
Current assignee: Omni Medsci Inc
Added 9/23/2026, 12:47:36 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US9885698B2
Title: Near-infrared lasers for non-invasive monitoring of glucose, ketones, HbA1C, and other blood constituents.
Patent number / application: US9885698B2; application US15/212,549, filed 2016-07-18; granted/publication date 2018-02-06.
Inventor / assignee: Inventor Mohammed N. Islam; original and current assignee Omni Medsci Inc.
Priority date: 2012-12-31 (listed as an assumption, not a legal conclusion). External priority is claimed from US14/109,007, US14/108,974, US14/108,995, and PCT/US2013/075700, all dated 2013-12-17. Anticipated expiration is listed as 2033-12-17.
Status: Expired – Fee Related (legal status stated as an assumption only).
Purpose: The patent concerns non-invasive monitoring of blood constituents—glucose, ketones, HbA1C, and others—using near-infrared lasers. The excerpt's keyword and term indices link the disclosure to light, LEDs, optical beams, fibers, blood, glucose, beta-D-glucose, HbA1C, ketones, constituent measurement, biological transmission, spectral/optical effects, and processing. The description also references skin, tissue, dermis, veins, finger nails, dental enamel, dentin, water, hemoglobin, cholesterol, urea, creatinine, collagen, and elastin, plus spectroscopic analysis (including Fourier transform infrared spectroscopy) and detection methods.
Plain-language scope: Based on the supplied text, the patent appears directed to shining near-infrared laser light through or into biological material (e.g., skin, tissue, nail, vein) via optical beams and fibers, detecting the resulting optical/spectral signal, and processing measurements to determine levels of blood constituents such as glucose, ketones, and HbA1C without drawing blood.
Source: https://patents.google.com/patent/[US9885698](/patent/US9885698)/en
What the excerpt does not establish: The supplied text does not include the actual claims, abstract, full description, or drawings, so the precise claim scope, element combinations, and any limitations cannot be confirmed here. It also does not establish the accuracy of the legal status, priority date, assignee listing, or expiration date, all of which are expressly labeled assumptions or non-legal conclusions in the source. No litigation, ownership-transfer, validity, or prior-art analysis is undertaken.
Generated 10/1/2026, 9:54:17 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9885698. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.